150 related articles for article (PubMed ID: 21479980)
21. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
[TBL] [Abstract][Full Text] [Related]
22. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
[TBL] [Abstract][Full Text] [Related]
23. Lymphomatous polyposis as primary manifestation of mantle cell lymphoma.
Yu SC; Liu KL; Chang LC
Eur J Haematol; 2012 Aug; 89(2):185-6. PubMed ID: 22563740
[No Abstract] [Full Text] [Related]
24. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
[TBL] [Abstract][Full Text] [Related]
25. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
[TBL] [Abstract][Full Text] [Related]
27. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Tam CS; Khouri IF
Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
[TBL] [Abstract][Full Text] [Related]
28. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival.
Howard OM; Gribben JG; Neuberg DS; Grossbard M; Poor C; Janicek MJ; Shipp MA
J Clin Oncol; 2002 Mar; 20(5):1288-94. PubMed ID: 11870171
[TBL] [Abstract][Full Text] [Related]
29. [Clinical analysis of 140 cases of mantle cell lymphoma].
Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
[No Abstract] [Full Text] [Related]
30. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
[TBL] [Abstract][Full Text] [Related]
31. Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.
Reddy N; Greer JP; Goodman S; Kassim A; Morgan DS; Chinratanalab W; Brandt S; Englehardt B; Oluwole O; Jagasia MH; Savani BN
Exp Hematol; 2012 May; 40(5):359-66. PubMed ID: 22269117
[TBL] [Abstract][Full Text] [Related]
32. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O;
Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy: maintenance rituximab for relapsed follicular lymphoma.
Wrench D; Montoto S
Nat Rev Clin Oncol; 2010 Dec; 7(12):677-8. PubMed ID: 21116237
[No Abstract] [Full Text] [Related]
34. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
[TBL] [Abstract][Full Text] [Related]
35. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
36. Diffuse aggressive lymphoma.
Fisher RI; Miller TP; O'Connor OA
Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
[TBL] [Abstract][Full Text] [Related]
37. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
Andersen NS; Donovan JW; Zuckerman A; Pedersen L; Geisler C; Gribben JG
Exp Hematol; 2002 Jul; 30(7):703-10. PubMed ID: 12135667
[TBL] [Abstract][Full Text] [Related]
38. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
39. Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Hess G; Flohr T; Huber C; Kolbe K; Derigs HG; Fischer T
Bone Marrow Transplant; 2003 May; 31(9):775-82. PubMed ID: 12732884
[TBL] [Abstract][Full Text] [Related]
40. R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma.
Lim SH; Esler WV; Periman PO; Beggs D; Zhang Y; Townsend M
Br J Haematol; 2008 Jul; 142(3):482-4. PubMed ID: 18510683
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]